Poloxamer 188 - CytRx Corporation

Drug Profile

Poloxamer 188 - CytRx Corporation

Alternative Names: RheothRx

Latest Information Update: 27 Sep 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytRx Corporation
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Burns; Cancer; Malaria; Myocardial infarction; Respiratory distress syndrome; Stroke; Thrombosis

Most Recent Events

  • 27 Sep 2000 Discontinued-II for Respiratory distress syndrome in USA (Parenteral)
  • 27 Sep 2000 Discontinued-II for Stroke in USA (Parenteral)
  • 27 Sep 2000 Investigation in Burns in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top